Navigation

TA142 Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin: costing statement

A costing statement has been produced by NICE to provide an implementation tool to estimate the financial impact to the NHS of implementing the technology appraisal TA142, epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia.

The costing statement focuses on the financial impact of the key factors in this technical appraisal for England. The report has been prepared in consultation with the technical leads and has been approved for publication by the Institute. It should be noted that the cost and activity assessments in the report are estimates based on a number of assumptions. These assessments provide an indication of the likely impact of the principal recommendations and are not absolute figures.

The Institute would welcome feedback from users to inform the development of future costing tools. Please email your comments to costing@nice.org.uk

This page was last updated: 30 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.